Vismodegib Safe, Effective in Twelve-Month Study Update
the Cancer Therapy Advisor take:
Vismodegib is safe and effective in the management of advanced basal cell carcinoma (BCC), according to a study published in the Journal of the American Academy of Dermatology.
In a multinational, multicenter, nonrandomized, two-cohort study, researchers led by Aleksander Sekulic, MD, of the Mayo Clinic looked at patients with measurable and histologically confirmed locally advanced or metastatic BCC who took oral vismodegib.
Primary outcome was objective response rate, both complete and partial, which was assessed by an independent review facility.
The researchers found that after 12 months of primary analysis, median duration of exposure to vismodegib was 12.9 months. In patients with metastatic disease, objective response rate increased from 30.3 percent to 33.3 percent, while in those with locally advanced disease, it increased from 42.9 percent to 47.6 percent.
In addition, median duration of response in patients with locally advanced disease increased from 7.6 to 9.5 months.
“The 12-month update of the study confirms the efficacy and safety of vismodegib in management of advanced BCC,” the authors concluded.
Vismodegib is safe and effective in the management of advanced basal cell carcinoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pancreatitis and the Risk of Cancer
- RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer
- Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer
- Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances
- Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma
- CTC Screening May Be Effective Method for Preventing Colorectal Cancer
- Physical Activity Intervention May Improve Functional Well-being Among CRC Survivors
- Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC
- Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC
- Alcohol Consumption and Cancer